在复杂的记忆测试中的表现与患阿尔茨海默病风险较高的人群中β-粉胺有关
Pernille Louise Kjeldsen1,2,3, Malene Flensborg Damholdt1,4, Lasse Stensvig Madsen1,5
1Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Journal of neuropsychology
|June 29, 2023
概括
敏感的记忆测试,特别是口头和关联性测试,可以检测早期的阿尔茨海默病 (AD) 变化,与携带阿波利波蛋白E (APOE) ε4等位基因的危险人群中的β-粉样蛋白 (Aβ) 积累相关.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 病理学,包括β-粉样蛋白 (Aβ) 积累,在临床症状出现前几年就开始.
- 无脂蛋白E (APOE) ε4等位基因是AD的重要遗传风险因素,与早期的Aβ沉积有关.
- 标准认知测试可能无法检测早期的Aβ相关认知障碍,需要采取更敏感的措施.
研究的目的:
- 调查Aβ负载与风险人群口头,视觉和关联性记忆测试中的表现之间的关联.
- 确定哪些记忆子域对APOE ε4载体中早期Aβ相关的认知变化最敏感.
主要方法:
- 55名APOE ε4载体接受了MRI,11C-匹兹堡化合物B (PiB) PET用于Aβ成像和认知测试.
- 根据PiB PET SUVR,对象被分为Aβ阳性 (APOE ε4 Aβ+) 和Aβ阴性 (APOE ε4 Aβ-) 组.
- 皮层表面分析被用来将Aβ负载与记忆测试性能相关联.
主要成果:
- 在整体APOE ε4组中,Aβ负载与口头,视觉和关联性记忆相关,与关联性记忆的联系最强.
- 在APOE ε4 Aβ+组中,Aβ负载与口头和关联性记忆相关,但与视觉记忆无关.
- 这些相关性分别在广泛和局部皮质区域观察到.
结论:
- 口头和关联记忆测试作为早期Aβ相关认知障碍的敏感指标,在患AD风险较高的人群中.
- 这些发现凸显了特定记忆评估在风险人群中早期检测AD病理生理学的潜力.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.5K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
